Sharma Videha, Roy Reuben, Piscoran Oana, Summers Angela, van Dellen David, Augustine Titus
Manchester University Hospitals NHS Foundation Trust, Manchester, UK and University of Manchester, Manchester, UK
Manchester University Hospitals NHS Foundation Trust, Manchester, UK.
Clin Med (Lond). 2020 May;20(3):346-348. doi: 10.7861/clinmed.2020-0047.
Transplantation is the preferred treatment option for end-stage renal disease as it offers superior results and patient reported outcomes in comparison to dialysis. Patients treated with a transplant live longer, healthier and more independent lives. Transplantation is also more cost-effective, reducing the overall burden of renal disease. Despite the rising incidence of renal failure, the uptake of living donor kidney transplantation has been static across the UK for several years. Among transplantation, living donation offers a number of advantages compared with deceased donor transplantation. The procedure is more likely to be performed pre-dialysis and the elective nature allows for better perioperative planning. Awareness for living donation processes among healthcare professionals, patients and the public appears to be poor. Sharing information regarding the process will help educate colleagues, dispel myths and, crucially, allow patients the opportunity to talk about this treatment option with their hospital doctor.
移植是终末期肾病的首选治疗方案，因为与透析相比，它能带来更好的治疗效果和患者报告结局。接受移植治疗的患者寿命更长、生活更健康、更独立。移植也更具成本效益，减轻了肾病的总体负担。尽管肾衰竭发病率不断上升，但活体供肾移植在英国的接受率多年来一直停滞不前。在移植中，与 deceased donor transplantation（此处原文有误，可能是“deceased donor transplantation”，意为“尸体供肾移植”）相比，活体捐赠具有许多优势。该手术更有可能在透析前进行，且其选择性性质允许进行更好的围手术期规划。医疗保健专业人员、患者和公众对活体捐赠过程的认知似乎较差。分享有关该过程的信息将有助于教育同事、消除误解，至关重要的是，让患者有机会与他们的医院医生谈论这种治疗选择。
